---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004080"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:08:27.887913+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Intellia restructures to focus on NTLA-2002 and nex-z, cuts 27% headcount, extends cash runway to H1 2027

## Summary
- Preliminary cash, cash equivalents and investments of $862M as of Dec 31, 2024.
- Strategic restructuring: prioritize NTLA-2002 and nex-z; discontinue NTLA-3001 and select research programs.
- Net workforce reduction of approximately 27% in 2025; estimated $8M restructuring charges in Q1 2025.
- Cash runway extended to first half of 2027.
- CSO Laura Sepp-Lorenzino to retire Dec 31, 2025; Birgit Schultes promoted to EVP and CSO effective Jan 13, 2025.

## SEC filing metadata
- accession: 0001193125-25-004080
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/0001193125-25-004080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/d906527d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004080
- JSON: https://secwatch.observer/filing/0001193125-25-004080.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004080.txt

## Key facts
- Executive change
  Laura Sepp-Lorenzino departed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..
  - Action: will retire
  - Role: Executive Vice President and Chief Scientific Officer
  source text: Laura Sepp-Lorenzino, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer (“CSO”), will retire from the Company and that her anticipated retirement date is December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/0001193125-25-004080-index.htm
- Executive change
  Laura Sepp-Lorenzino changed role as Special Advisor to the Chief Executive Officer at Intellia Therapeutics, Inc..
  - Action: will become
  - Role: Special Advisor to the Chief Executive Officer
  source text: effective January 13, 2025, Dr. Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/0001193125-25-004080-index.htm
- Executive change
  Birgit Schultes was appointed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..
  - Action: will become
  - Role: Executive Vice President and Chief Scientific Officer
  source text: Birgit Schultes, Ph.D. will become the Company’s Executive Vice President and CSO, effective as of January 13, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312525004080/0001193125-25-004080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.